Biotech and Pharmaceuticals
AbbVie taps longtime executive Robert Michael as new CEO, succeeding Richard Gonzalez
Test tubes are seen in front of a displayed AbbVie logo in this illustration taken on May 21, 2021. Dado Ruvic | Reuters AbbVie on Tuesday said longtime executive Robert Michael will become the company’s new CEO, replacing Richard Gonzalez. Michael, who is AbbVie’s president and chief operating officer, will become the company’s second-ever CEO […]
Read More
Elon Musk states initial Neuralink individual can regulate a personal computer mouse by way of thinking
Jonathan Raa | Nurphoto | Getty Illustrations or photos A affected person implanted with Neuralink’s mind technological know-how can now handle a laptop mouse just by considering, the firm’s founder Elon Musk reported. “(The) patient seems to have built a complete recovery with no ill effects that we are mindful of and is equipped to […]
Read More
'This is the mental health moment': Innovation and M&A are helping to boost these stocks to new heights
There’s been a lot of chatter about the mental health crisis since the Covid-19 pandemic. Overall, 12 mental health disorders affect 970 million people around the world — or one in eight people, according to the Institute for Health Metrics and Evaluation’s Global Burden of Disease. That can mean anything from anxiety and depression to […]
Read More
These are the only 2 ETFs that created dollars every single 12 months for the earlier decade
Two funds investing in defensive shares are the only trade-traded funds in the world that had a good return each yr in excess of the earlier 10 years, CNBC Professional research has discovered. The Amundi ETF MSCI Europe Healthcare UCITS ETF , traded on the London Stock Exchange, and the Canadian customer staples iShares S […]
Read More
What Eli Lilly investors can learn from the slow launch of a competitor's drug
Club holding Eli Lilly is expecting to get approval for its Alzheimer’s treatment in the coming weeks, but investors looking for immediate financial success should temper their expectations. On its fourth-quarter earnings call Tuesday, rival drugmaker Biogen shared data that showed its therapy for the memory-robbing disease, Leqembi, is off to a slower-than-expected start. In […]
Read More
Biden administration examining role of supply chain middlemen in generic drug shortages
A variety of generic pills and capsules. Nenov | Moment | Getty Images The Federal Trade Commission on Wednesday said it is examining the role that drug wholesalers and companies that purchase medicines for U.S. health-care providers play in shortages of generic drugs, which account for the majority of Americans’ prescriptions. The move follows an […]
Read More
Healthy Returns: Higher medical costs are pinching insurers
A UnitedHealth Group health insurance card is seen in a wallet, Oct.14, 2019. Lucy Nicholson | Reuters Good afternoon! Health insurers are feeling the squeeze as older patients head to the doctor more than expected. CVS, which owns health insurer Aetna, on Wednesday slashed its full-year profit outlook, citing the potential for higher medical costs to bite […]
Read More
Federal judge tosses lobbying group's lawsuit challenging Medicare drug price negotiations
Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services (HHS) building on October 06, 2022 in Washington, DC. Anna Moneymaker | Getty Images A federal judge on Monday tossed a lawsuit brought by a major pharmaceutical industry lobbying group and two other organizations, which challenged […]
Read More
Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
Biogen on Tuesday reported fourth-quarter revenue and profit that shrank from a year ago, as it recorded charges related to dropping its controversial Alzheimer’s drug Aduhelm and as sales slumped in its multiple sclerosis therapies, the company’s biggest drug category. Biogen booked sales of $2.39 billion for the quarter, down 6% from the same period a […]
Read More
Wall Street changes its tune on this healthcare stock. Why we were always bullish
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Monday’s key moments. 1. U.S. stocks were modestly higher Monday as the market awaits key economic data. Traders will be mulling over the consumer price index Tuesday, retail sales Thursday, and the producer […]
Read More